Form 4: Viking Therapeutics CFO Reports Stock Transactions

Viking Therapeutics' Chief Financial Officer, Greg Zante, reported the vesting of performance-based restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Greg Zante, Chief Financial Officer of Viking Therapeutics, Inc. (VKTX), reported transactions involving the company's common stock.
• On October 27, 2025, Mr. Zante acquired 11,117 shares of common stock at a price of $0.
• These shares were acquired due to the vesting of a performance restricted stock unit (RSU) award that was granted on January 3, 2025.
• The vesting occurred because 33.33% of the award vested upon achieving a non-financial performance goal, and an additional 15% vested upon the partial achievement of another non-financial performance goal.
• Following this acquisition, Mr. Zante's beneficial ownership increased to 179,777 shares.
• On October 28, 2025, Mr. Zante disposed of 6,185 shares of common stock at a weighted average price of $35.0009 per share.
• This sale was non-discretionary and solely to satisfy certain tax withholding obligations in connection with the RSU vesting.
• The shares were sold in multiple transactions at prices ranging from $34.6525 to $35.3939.
• After the disposition, Mr. Zante's beneficial ownership stands at 173,592 shares.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the vesting of performance-based restricted stock units, indicating achievement of company goals. The subsequent sale of shares is a routine tax-related event and does not reflect negatively on the company's prospects.

Positives

• The vesting of 11,117 performance restricted stock units indicates the achievement of specific non-financial performance goals by the company or the executive.
• The vesting demonstrates management's alignment with company performance objectives through equity compensation.

Negatives

• The sale of 6,185 shares, although for tax purposes, results in a reduction of the Chief Financial Officer's direct ownership stake in the company.

Future Outlook

This Form 4 filing reports past transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine insider transaction report for an executive at a publicly traded biotechnology company. Such filings are common across all industries and reflect standard equity compensation practices and tax obligations, rather than specific industry trends.

Stakeholder Impact

• Shareholders: Minor impact. The CFO's beneficial ownership slightly decreased due to a tax-related sale, but the underlying vesting indicates performance goal achievement, which is generally positive.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and subsequent tax-related share sales). It does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The vesting of performance-based awards is generally a positive sign, but the overall impact on the company's valuation or future prospects is minimal from this filing alone. Therefore, a 'hold' recommendation is appropriate, pending further substantive company announcements.

Keywords

Viking Therapeutics, VKTX, Greg Zante, CFO, Insider Trading, Form 4, Stock Transaction, Restricted Stock Unit, RSU Vesting, Tax Withholding, Equity Compensation